DuPont completes Danisco tender offer for DKK 700 per share

NewsGuard 100/100 Score

DuPont (NYSE: DD), through its wholly owned subsidiary DuPont Denmark Holding ApS, announced today that it has successfully completed its tender offer for all outstanding shares of common stock of Danisco for DKK 700 cash per share.  The tender offer expired on May 13, 2011, at 11 p.m. CEST (5 p.m. EDT).  

DuPont estimates that, as of the expiration of the offer on May 13, Danisco shareholders had tendered approximately 92.2 percent of the outstanding shares to DuPont Denmark Holding ApS.  All shares that were properly tendered have been accepted for purchase.  Payment for those shares will be made in accordance with the terms of the tender offer.  

"We are delighted that the tender has been successful and we can move on to the process of integrating Danisco into DuPont.  Danisco's attractive specialty food ingredients businesses and Genencor's leading industrial enzymes complement DuPont's own Nutrition & Health and Applied BioSciences offerings," said DuPont Chair and CEO Ellen Kullman.  "This combination will create an industry leader in industrial biosciences and nutrition and health.

"These businesses will work together to drive sustainable growth and market-driven innovation by linking agriculture, nutrition and advanced materials through industrial biosciences," Kullman said.  "In addition, the R&D combination of DuPont, Danisco and Genencor will enable us to further respond to global megatrends and help provide for the food, energy and protection needs of a growing population."

"We are very pleased that a vast majority of Danisco shareholders have accepted DuPont's offer and the two companies may now begin to move forward together," said Danisco Chairman Jorgen Tandrup.  "DuPont and Danisco share cultures based in exceptional science and research capabilities.  Our combined strengths in biosciences and nutrition and health will deliver innovative new offerings for customers worldwide, while helping to grow these businesses in ways that will benefit employees, shareholders and the communities in which we serve.  We look forward to this next exciting chapter of discovery and success for the joined companies."

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Food additive emulsifiers linked to increased risk of type 2 diabetes